Resources
27 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 12/24/2020 (updated 4/4/2024)
The Townhall TeleECHO presentation will introduce a monthly interactive opportunity for clinicians and their support staff to address challenges and share solutions and successes to gain confidence in addressing OUD with MOUD. The Behavioral Health Data Learning Collaborative presentation will introduce goals of understanding data and data sharing, use of indicators and data sources, and data driven programming and quality improvement. Open discussion will follow each presentation.
Posted 11/17/2021 (updated 4/3/2024)
The National Academies of Science, Engineering, and Medicine defines stigma as a range of negative attitudes, beliefs and behaviors that are associated with certain conditions such as addiction. Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), has been a leading voice in talking about the “chilling effect” stigma has on our ability to address substance use and addiction in our country. In an April 2020 perspective piece published in the New England Journal of Medicine and in her NIDA blog piece, Dr. Volkow explains how stigma can prevent people from seeking care and can even contribute to their continuing addiction. We encourage our visitors to read Dr. Volkow’s writings as well as to familiarize themselves with the efforts to reduce stigma led by the National Institutes of Health (NIH) including the NIH HEAL InitiativeSM, which has made addressing stigma a key element in their efforts to address opioid addiction.
Posted 11/11/2021 (updated 4/3/2024)
This session provided a deep dive into what a peer provider is and confront the direct and indirect challenges and solutions peer providers face.
Posted 10/26/2021 (updated 4/3/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 9/4/2020 (updated 3/29/2024)
Like all professions, the addictions treatment field is faced with the challenges of employee substance use and abuse and their impact on retention of quality staff. Because the addictions field employees a disproportionate number of individuals – by recent estimates close to half of the treatment workforce – in recovery, the field faces particular retention challenges. This toolkit provides meaningful and practical guidance to the problem of substance misuse among addictions professionals.
Posted 2/10/2020 (updated 3/28/2024)
ONDCP released a new tool to assist rural community leaders in building an effective local response to the crisis of addiction, the Rural Community Action Guide: Building Stronger, Healthy Drug-Free Rural Communities. The Guide also has a companion supplement, a listing of promising practices, included.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 5, 2020, at 2:30 PM